CD248 and its cytoplasmic domain: a therapeutic target for arthritis - PubMed (original) (raw)
Comparative Study
. 2010 Dec;62(12):3595-606.
doi: 10.1002/art.27701.
Affiliations
- PMID: 20722022
- DOI: 10.1002/art.27701
Free article
Comparative Study
CD248 and its cytoplasmic domain: a therapeutic target for arthritis
Margarida Maia et al. Arthritis Rheum. 2010 Dec.
Free article
Abstract
Objective: CD248 is a transmembrane glycoprotein expressed on the surface of activated perivascular and fibroblast-like cells. This study was undertaken to explore the function of CD248 and its cytoplasmic domain in arthritis.
Methods: Synovial tissue biopsy samples from healthy controls, from patients with psoriatic arthritis (PsA), and from patients with rheumatoid arthritis (RA) were stained for CD248. Transgenic mice that were CD248-deficient (CD248-knockout [CD248(KO/KO) ]) or mice with CD248 lacking the cytoplasmic domain (CD248(CyD/CyD) ) were generated. Collagen antibody-induced arthritis (CAIA) was induced in these mice and in corresponding wild-type (WT) mice as controls. Clinical signs and histologic features of arthritis were evaluated. Cytokine levels were determined by enzyme-linked immunosorbent assay, and the number of infiltrating inflammatory cells was quantified by immunohistochemistry. In vitro studies were performed with fibroblasts from CD248-transgenic mouse embryos to explain the observed effects on inflammation.
Results: Immunostaining of synovium from patients with PsA and patients with RA and that from mice after the induction of CAIA revealed strong CD248 expression in perivascular and fibroblast-like stromal cells. CD248(KO/KO) and CD248(CyD/CyD) mice had less severe arthritis, with lower plasma levels of proinflammatory cytokines, as compared with WT controls. Moreover, the joints of these mice had less synovial hyperplasia, reduced accumulation of inflammatory cells, and less articular cartilage and bone damage. Tumor necrosis factor α-induced monocyte adhesion to CD248(CyD/CyD) fibroblasts was impaired. CD248(CyD/CyD) fibroblasts exhibited reduced expression of hypoxia-inducible factor 1α, placental growth factor, vascular endothelial growth factor, and matrix metalloproteinase 9 activity in response to transforming growth factor β.
Conclusion: CD248 contributes to synovial hyperplasia and leukocyte accumulation in inflammatory arthritis, the effects of which are mediated partly via its cytoplasmic domain. CD248 is therefore a potential new target in the treatment of arthritis.
Copyright © 2010 by the American College of Rheumatology.
Similar articles
- Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation.
Yoo SA, Yoon HJ, Kim HS, Chae CB, De Falco S, Cho CS, Kim WU. Yoo SA, et al. Arthritis Rheum. 2009 Feb;60(2):345-54. doi: 10.1002/art.24289. Arthritis Rheum. 2009. PMID: 19180491 - Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment.
van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. van Kuijk AW, et al. Ann Rheum Dis. 2006 Dec;65(12):1551-7. doi: 10.1136/ard.2005.050963. Epub 2006 May 25. Ann Rheum Dis. 2006. PMID: 16728461 Free PMC article. - CD248 facilitates tumor growth via its cytoplasmic domain.
Maia M, DeVriese A, Janssens T, Moons M, Lories RJ, Tavernier J, Conway EM. Maia M, et al. BMC Cancer. 2011 May 8;11:162. doi: 10.1186/1471-2407-11-162. BMC Cancer. 2011. PMID: 21549007 Free PMC article. - Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy.
van Kuijk AW, Tak PP. van Kuijk AW, et al. Curr Rheumatol Rep. 2011 Aug;13(4):353-9. doi: 10.1007/s11926-011-0181-y. Curr Rheumatol Rep. 2011. PMID: 21503693 Free PMC article. Review. - Macrophages, synovial tissue and rheumatoid arthritis.
Cutolo M, Sulli A, Barone A, Seriolo B, Accardo S. Cutolo M, et al. Clin Exp Rheumatol. 1993 May-Jun;11(3):331-9. Clin Exp Rheumatol. 1993. PMID: 8394794 Review.
Cited by
- Novel antibody probes for the characterization of endosialin/TEM-1.
O'Shannessy DJ, Smith MF, Somers EB, Jackson SM, Albone E, Tomkowicz B, Cheng X, Park Y, Fernando D, Milinichik A, Kline B, Fulton R, Oberoi P, Nicolaides NC. O'Shannessy DJ, et al. Oncotarget. 2016 Oct 25;7(43):69420-69435. doi: 10.18632/oncotarget.11018. Oncotarget. 2016. PMID: 27494870 Free PMC article. - CD248: A therapeutic target in cancer and fibrotic diseases.
Teicher BA. Teicher BA. Oncotarget. 2019 Jan 29;10(9):993-1009. doi: 10.18632/oncotarget.26590. eCollection 2019 Jan 29. Oncotarget. 2019. PMID: 30847027 Free PMC article. Review. - Targeting pathogenic fibroblast-like synoviocyte subsets in rheumatoid arthritis.
Qian H, Deng C, Chen S, Zhang X, He Y, Lan J, Wang A, Shi G, Liu Y. Qian H, et al. Arthritis Res Ther. 2024 May 23;26(1):103. doi: 10.1186/s13075-024-03343-4. Arthritis Res Ther. 2024. PMID: 38783357 Free PMC article. Review. - Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis.
Bartis D, Crowley LE, D'Souza VK, Borthwick L, Fisher AJ, Croft AP, Pongrácz JE, Thompson R, Langman G, Buckley CD, Thickett DR. Bartis D, et al. BMC Pulm Med. 2016 Apr 14;16(1):51. doi: 10.1186/s12890-016-0211-7. BMC Pulm Med. 2016. PMID: 27080864 Free PMC article. - TEM1/endosialin/CD248 promotes pathologic scarring and TGF-β activity through its receptor stability in dermal fibroblasts.
Hong YK, Lin YC, Cheng TL, Lai CH, Chang YH, Huang YL, Hung CY, Wu CH, Hung KS, Ku YC, Ho YT, Tang MJ, Lin SW, Shi GY, McGrath JA, Wu HL, Hsu CK. Hong YK, et al. J Biomed Sci. 2024 Jan 23;31(1):12. doi: 10.1186/s12929-024-01001-0. J Biomed Sci. 2024. PMID: 38254097 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous